Teva Pharmaceutical Industries Limited (NYSE:TEVA) had its price objective cut by Royal Bank Of Canada from $21.00 to $15.00 in a report released on Monday morning, MarketBeat reports. They currently have an underperform rating on the stock.

TEVA has been the topic of several other reports. TheStreet cut shares of Teva Pharmaceutical Industries Limited from a c- rating to a d+ rating in a research note on Friday, August 25th. ValuEngine cut shares of Teva Pharmaceutical Industries Limited from a buy rating to a hold rating in a research note on Friday, September 1st. Vetr cut shares of Teva Pharmaceutical Industries Limited from a strong-buy rating to a buy rating and set a $31.94 price objective on the stock. in a research note on Monday, May 22nd. Deutsche Bank AG reaffirmed a buy rating and set a $28.00 price objective (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Finally, Credit Suisse Group cut shares of Teva Pharmaceutical Industries Limited from a neutral rating to an underperform rating and decreased their price objective for the stock from $25.00 to $13.00 in a research note on Wednesday, August 23rd. Five research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $30.91.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 17.15 on Monday. The stock’s 50 day moving average price is $18.13 and its 200 day moving average price is $28.20. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $51.51. The firm’s market capitalization is $17.42 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.25 earnings per share. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Price Target Cut to $15.00” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/22/teva-pharmaceutical-industries-limited-teva-price-target-cut-to-15-00.html.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were issued a $0.085 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 1.98%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -15.36%.

Large investors have recently modified their holdings of the stock. San Francisco Sentry Investment Group CA acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the second quarter worth $106,000. Bronfman E.L. Rothschild L.P. raised its holdings in shares of Teva Pharmaceutical Industries Limited by 7.8% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after acquiring an additional 261 shares during the period. Kistler Tiffany Companies LLC raised its holdings in shares of Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after acquiring an additional 1,571 shares during the period. FNY Managed Accounts LLC acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter worth $123,000. Finally, Sterling Investment Advisors Ltd. raised its holdings in shares of Teva Pharmaceutical Industries Limited by 2.6% during the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 56.76% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.